Skip to content

Restoring Immune Homeostasis

An Integrated Strategy to Correcting Immune System Dysregulation

Homeostasis Disrupted

Autoimmune and inflammatory diseases result from dysregulation of the healthy immune response, rooted in either the adaptive or innate immune systems. These diseases affect every organ system and cause dramatically decreased quality of life and significant morbidity and mortality for tens of millions of patients worldwide. For many of these diseases, treatment options are inadequate or absent altogether. Systemic immunomodulators are helpful in disease management but they often deliver inadequate efficacy and are associated with treatment-limiting side effects that can be severe.

Insight, Expertise, Approach

To meet the need for therapies that safely address underlying immune dysregulation, Q32 Bio has developed an integrated portfolio of therapies to modulate the innate and adaptive immune responses. Our company's mission is to bring safer, more efficacious therapeutics to patients suffering from a wide range of devastating autoimmune and inflammatory diseases, starting with those rooted in the complement system and interleukin-7 (IL-7)/ thymic stromal lymphopoietin (TSLP) signaling pathways. In pursuit of our bold vision, Q32 Bio has assembled leaders in the field of immunology uniquely positioned to develop novel biologics based on the body’s innate and adaptive immune systems. Our lead molecules include therapeutic fusion proteins that deliver negative regulators of complement activation directly to disease-affected tissues and a monoclonal antibody antagonist of the IL-7/TSLP receptors.

Presentations

Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021

Our Pipeline

Q32 Bio has advanced a strong clinical and discovery pipeline based on the body’s innate and adaptive immune systems and the drive to restore immune homeostasis in patients with severe inflammatory and autoimmune diseases.

Our Team

With an expert team comprised of highly skilled drug developers and immunology experts from the biotech/biopharma industry, Q32 Bio is well-positioned to deliver on its mission to bring new therapeutics to patients with severe inflammatory and autoimmune diseases.

News

Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition

–Jodie Morrison appointed as Board Member and Acting CEO– Waltham, Mass. – September 20, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson. “Jodie has a deep background in executive, operational and […] Read More >

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

Waltham, Mass. and Dublin – August 15, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases. ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive […] Read More >

Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097

Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition Waltham, Mass. – June 23, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the Company presented new preclinical data demonstrating the therapeutic potential of […] Read More >

Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia “Resolution of Inflammation” Conference

Dr. Violette also organizing the “Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies” conference at the Keystone Symposia Waltham, Mass. – June 8, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that its Founder and Chief Scientific Officer, Shelia Violette, Ph.D., will present “Targeting Complement in […] Read More >

Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders

First clinical-stage program from Q32 Bio’s tissue targeted complement inhibitor platform Clinical-stage pipeline now consists of two programs in development to restore immune homeostasis Waltham, Mass. – May 26, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that dosing has been initiated in the healthy volunteer portion […] Read More >

Q32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021

C3d targeted fusion proteins enable highly specific tissue-targeted complement system inhibition ADX-097 has the potential to provide increased potency, decreased dosing frequency and improved safety in severe inflammatory and autoimmune diseases Cambridge, Mass. – December 13, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data for […] Read More >

Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021

Data demonstrate ADX-097’s ability to precisely target complement blockade to diseased tissue In multiple renal disease models, ADX-097 potently inhibits disease-causing complement activation while avoiding systemic complement inhibition Cambridge, Mass. – November 8, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data from the Company’s lead […] Read More >

Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021

Cambridge, Mass. – October 18, 2021 – Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that it will present preclinical data supporting the Company’s lead program for innate immunity, ADX-097, during an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2021, taking place virtually from November 4 […] Read More >

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors

Cambridge, Mass. – August 3, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors. Ms. LaPorte, who brings over 30 years of experience in executive leadership and venture investing within the biotech industry, will serve as the Chair […] Read More >

Q32 Bio Appoints Adam Cutler as Chief Financial Officer

Cambridge, Mass. – July 7, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Adam Cutler as Chief Financial Officer. Mr. Cutler will be responsible for all aspects of Q32’s financial strategy and operations. Read More >

Q32 Bio to Present at the Jefferies Virtual Healthcare Conference

Cambridge, Mass. – May 27, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that Michael Broxson, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 pm ET. Read More >

Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer

Cambridge, Mass. (March 9, 2021) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna, M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team during a critical growth and development period for the company. Read More >

Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors

Cambridge, Mass. (December 22nd, 2020) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of their Board of Directors. Mr. Iwicki will succeed Dr. David Grayzel as Chairman. Dr. Grayzel, an Atlas Venture partner and co-founder of Q32, will continue as a Director. Read More >

Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis

Cambridge, Mass. (October 29, 2020) – Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures. The company also announced the commencement of a Phase 1 clinical trial evaluating its best-in-class IL-7R antibody ADX-914, a significant milestone marking Q32 Bio’s entry into clinical-stage development. Read More >

Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity

Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020 Read More >

Q32 Bio is a Proud Supporter of Life Science Cares

Read More >